Background Currently, there are no direct comparisons of apixaban and rivaroxaban, two
new oral direct factor Xa inhibitors approved for management of thromboembolic disorders …

Background Anticoagulation with low molecular weight heparin and vitamin K antagonists is
the current standard of care (SOC) for venous thromboembolism (VTE) treatment and …

Background Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin
in patients with venous thromboembolism is unclear. Methods In a randomized, double …

Background The AMPLIFY trial compared apixaban with enoxaparin followed by warfarin for
the treatment of acute venous thromboembolism (VTE). Objective To perform a subgroup …

Introduction Apixaban is an oral direct factor Xa inhibitor developed for the prophylaxis and
treatment of thromboembolic disorders. Laboratory monitoring is not necessary, but the …

The new oral anticoagulants (NOACs), which include dabigatran, rivaroxaban, apixaban,
and edoxaban, are poised to replace warfarin for treatment of the majority of patients with …

Abstract Apixaban (BMS-562247; 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)
phenyl)-4, 5, 6, 7-tetrahydro-1 H-pyrazolo [3, 4-c] pyridine-3-carboxamide), a direct inhibitor …

Venous thromboembolism (VTE) is a common disease associated with high risk for
recurrences, death, and late sequelae, accounting for substantial health care costs …

Background: Apixaban is an oral, direct and highly selective factor Xa (FXa) inhibitor in late‐
stage clinical development for the prevention and treatment of thromboembolic diseases …

Background A fixed-dose regimen of rivaroxaban, an oral factor Xa inhibitor, has been
shown to be as effective as standard anticoagulant therapy for the treatment of deep-vein …